about
The incidence and cause of coagulopathies in an intensive care population.Nonhematopoietic antigen blocks memory programming of alloreactive CD8+ T cells and drives their eventual exhaustion in mouse models of bone marrow transplantation.OX40- and CD27-mediated costimulation synergizes with anti-PD-L1 blockade by forcing exhausted CD8+ T cells to exit quiescence.Conventional dendritic cells are required for the activation of helper-dependent CD8 T cell responses to a model antigen after cutaneous vaccination with lentiviral vectors.Role of dendritic cells in graft-versus-host disease.CD8 T cell tolerance to a tumor-associated self-antigen is reversed by CD4 T cells engineered to express the same T cell receptorVitamin D and barrier function: a novel role for extra-renal 1 alpha-hydroxylase.Host MHC class II+ antigen-presenting cells and CD4 cells are required for CD8-mediated graft-versus-leukemia responses following delayed donor leukocyte infusionsAn inflammatory checkpoint regulates recruitment of graft-versus-host reactive T cells to peripheral tissuesAdoptive transfer of cytomegalovirus-specific CTL to stem cell transplant patients after selection by HLA-peptide tetramersDepletion of CD11c⁺ cells in the CD11c.DTR model drives expansion of unique CD64⁺ Ly6C⁺ monocytes that are poised to release TNF-αExpression of a dominant T-cell receptor can reduce toxicity and enhance tumor protection of allogeneic T-cell therapy.Regulatory mechanisms in graft-versus-host responses.Allogeneic transplantation for lymphoma.Dendritic Cells Cross-Present Immunogenic Lentivector-Encoded Antigen from Transduced Cells to Prime Functional T Cell Immunity.Genetic Regulation of Fate Decisions in Therapeutic T Cells to Enhance Tumor Protection and Memory Formation.Specificity for the tumor-associated self-antigen WT1 drives the development of fully functional memory T cells in the absence of vaccination.Favorable long-term survival after reduced-intensity allogeneic transplantation for multiple-relapse aggressive non-Hodgkin's lymphoma.Generation of memory T cells for adoptive transfer using clinical-grade anti-CD62L magnetic beads.CMV promotes recipient T-cell immunity following reduced-intensity T-cell-depleted HSCT, significantly modulating chimerism status.An unexpected role for platelets in blocking Th17 differentiation.Langerhans cells regulate cutaneous injury by licensing CD8 effector cells recruited to the skinThe role of antigen-presenting cells in triggering graft-versus-host disease and graft-versus-leukemia.EBV-associated post-transplant lymphoproliferative disorder following in vivo T-cell-depleted allogeneic transplantation: clinical features, viral load correlates and prognostic factors in the rituximab era.T-cell-depleted reduced-intensity transplantation followed by donor leukocyte infusions to promote graft-versus-lymphoma activity results in excellent long-term survival in patients with multiply relapsed follicular lymphoma.Impact of in vivo alemtuzumab dose before reduced intensity conditioning and HLA-identical sibling stem cell transplantation: pharmacokinetics, GVHD, and immune reconstitution.HLA-mismatched unrelated donors are a viable alternate graft source for allogeneic transplantation following alemtuzumab-based reduced-intensity conditioning.Directly selected cytomegalovirus-reactive donor T cells confer rapid and safe systemic reconstitution of virus-specific immunity following stem cell transplantation.Memory lapses in graft-versus-host disease.Cell-intrinsic regulation of murine dendritic cell function and survival by prereceptor amplification of glucocorticoid.Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen.Inactivation of homologous recombination suppresses defects in topoisomerase III-deficient mutants.Differential regulation of vitamin D receptor and its ligand in human monocyte-derived dendritic cells.Incidence and dynamics of Epstein-Barr virus reactivation after alemtuzumab-based conditioning for allogeneic hematopoietic stem-cell transplantation.A highly compact epitope-based marker/suicide gene for easier and safer T-cell therapy.Gene therapy for Wiskott-Aldrich syndrome in a severely affected adult.Donor lymphocyte infusions modulate relapse risk in mixed chimeras and induce durable salvage in relapsed patients after T-cell-depleted allogeneic transplantation for Hodgkin's lymphoma.Expression of 11beta-hydroxysteroid dehydrogenase type 1 permits regulation of glucocorticoid bioavailability by human dendritic cells.Maturation of human monocyte-derived dendritic cells (MoDCs) in the presence of prostaglandin E2 optimizes CD4 and CD8 T cell-mediated responses to protein antigens: role of PGE2 in chemokine and cytokine expression by MoDCs.Apoptosis in mesenchymal stromal cells induces in vivo recipient-mediated immunomodulation.
P50
Q33495807-84A46A63-BF6A-4EDA-A13A-A3F06538986FQ34245299-69869041-292D-4649-950E-BC4D06DE39AEQ34749303-28CE65D9-EA13-42D1-AB6C-F1C256DDB400Q34767725-AE120592-01AE-47A3-B22E-1EDAE4194F2EQ34803083-76F437A3-9E8C-43C1-83CB-AE86848F9B55Q34981606-D5CB235B-AD73-40ED-93B3-B5D32255ECB6Q35693619-D7B51841-3B5E-4CD8-9E55-2ED55FB1739FQ35849099-ED68BAC1-A407-46EA-9B68-87AAEF0943F3Q36228795-910C213A-F815-4EF6-B7B5-772DFE83A951Q36403280-0188EE0B-5A9A-4085-BFF7-4C1DF4CDA77FQ36490200-2AA3CB33-9A1C-453A-A36E-C2A518D15510Q37216330-96559ED8-6117-4107-9658-E595BA1FB88CQ37369370-87371249-C399-4C6F-9069-1A601D0160C8Q37863994-B18B7C95-9EE4-49B4-B164-2C0543EBB043Q38762699-2962F781-203D-4A1E-AAC3-3FBC686C8EF9Q38883261-4BD2F86A-AD44-49E9-BD21-C41F7497122AQ39568612-7AC8B144-D46F-4CAE-9CDD-1AD133315256Q40020440-D1B47F9D-679B-4D67-98F8-EB289A26D416Q41160104-FBAA8327-B6CE-4C86-92CF-2868B77F1665Q41603310-33213976-66D6-43D0-AE85-8013813DED05Q41833758-FD21A68C-F96E-43E4-8D31-D7FC6A33461FQ42135895-46816D30-F4E1-4799-9147-F9663F5D43F6Q42151172-826E08B6-2FFE-4352-94D6-7EE34A38B8BFQ42256599-D4CF26BF-87F0-417A-B8EA-B0A994858CC1Q42981942-D01DBBD6-0EFE-4280-BBCE-2CA2A5075DA4Q43001701-856CE58A-4A53-4149-B32F-F065371170AFQ43108048-F1D8CC95-BBDD-4CF9-A844-CA69DA387B08Q43406230-664CDD2A-DB34-45B2-A10F-3B463C949BC8Q43443166-9A886A9B-8E18-488C-BFAF-3BBD805EE8E5Q43666154-7DA70F89-CBDD-4BD7-BADC-FEA08DC96304Q43863962-7ACE7EB0-ED45-470F-9232-46681858E15BQ44267600-2F7CE12D-3354-42FC-A0E1-E230E1E8E0DCQ44448880-C8A98418-1C14-4CA6-8471-AC1C9461B0E0Q45375211-073F98B6-183B-43B0-81E3-43265EC20CE1Q45866398-CC2ABC2F-FA94-47EA-8DDC-7B9CB49300A9Q45869832-343AFA26-9B88-4DDD-A676-BF4BEDC74EACQ45968368-34EFD43C-2717-4ABC-BF7B-DD2206C8B590Q46533251-9A534F2C-3EDC-40B0-AADA-F8D770ADE7EBQ46816706-B7A39952-53B9-4E99-BA00-F7C93131E37FQ47564842-3FFDA0BD-DA25-498C-A2C0-1478D63794DE
P50
description
researcher ORCID ID = 0000-0003-2301-2664
@en
name
Ronjon Chakraverty
@ast
Ronjon Chakraverty
@en
Ronjon Chakraverty
@es
Ronjon Chakraverty
@nl
type
label
Ronjon Chakraverty
@ast
Ronjon Chakraverty
@en
Ronjon Chakraverty
@es
Ronjon Chakraverty
@nl
prefLabel
Ronjon Chakraverty
@ast
Ronjon Chakraverty
@en
Ronjon Chakraverty
@es
Ronjon Chakraverty
@nl
P1153
6701831494
P21
P31
P496
0000-0003-2301-2664